Susquehanna International Group, LLP Actinium Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$6.56 - $9.89 $350,960 - $529,115	-53,500 Reduced 56.43%	41,300 $305,000
Q1 2024 May 07, 2024	BUY	$5.0 - $9.2 $71,500 - $131,560	14,300 Added 17.76%	94,800 $742,000
Q4 2023 Feb 14, 2024	SELL	$4.02 - $6.08 $803 - $1,216	-200 Reduced 0.25%	80,500 $408,000
Q3 2023 Nov 14, 2023	BUY	$5.91 - $7.37 $324,459 - $404,613	54,900 Added 212.79%	80,700 $477,000
Q2 2023 Aug 11, 2023	SELL	$7.15 - $9.39 $428,285 - $562,461	-59,900 Reduced 69.89%	25,800 $191,000
Q1 2023 May 16, 2023	BUY	$8.51 - $14.26 $281,681 - $472,006	33,100 Added 62.93%	85,700 $809,000
Q4 2022 Feb 14, 2023	SELL	$7.05 - $14.41 $549,900 - $1.12 Million	-78,000 Reduced 59.72%	52,600 $560,000
Q3 2022 Nov 14, 2022	SELL	$4.81 - $8.48 $106,300 - $187,408	-22,100 Reduced 14.47%	130,600 $964,000
Q2 2022 Aug 15, 2022	BUY	$4.71 - $7.11 $402,234 - $607,194	85,400 Added 126.89%	152,700 $734,000
Q1 2022 May 16, 2022	SELL	$4.57 - $6.4 $202,451 - $283,520	-44,300 Reduced 39.7%	67,300 $344,000
Q4 2021 Feb 14, 2022	SELL	$6.01 - $8.8 $580,566 - $850,080	-96,600 Reduced 46.4%	111,600 $671,000
Q3 2021 Nov 15, 2021	BUY	$5.76 - $9.67 $811,584 - $1.36 Million	140,900 Added 209.36%	208,200 $1.85 Million
Q2 2021 Aug 11, 2021	BUY	$7.01 - $8.63 $16,824 - $20,712	2,400 Added 3.7%	67,300 $532,000
Q1 2021 May 17, 2021	BUY	$7.62 - $9.79 $211,836 - $272,162	27,800 Added 74.93%	64,900 $495,000
Q4 2020 Feb 16, 2021	BUY	$7.8 - $12.64 $209,040 - $338,752	26,800 Added 260.19%	37,100 $289,000
Q3 2020 Nov 16, 2020	BUY	$7.26 - $18.0 $74,778 - $185,400	10,300 New	10,300 $100,000

Others Institutions Holding ATNM

# of Institutions

Shares Held

8.33M

Call Options Held

65.2K

Put Options Held

21.7K

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $41.6M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account